|
I took a position at $2.50...With 7.3 million sh. at 2 1/2= $18.25 million company value, it is an extremely interesting speculation...The company has some $14 million in cash...The C.E.O. is the ex-C.E.O. of Neurogen...I like the labs they are working with, e.g., Johns Hopkins, U.C.S.F., etc...It is not that this is not risky...However, when the technology is valued at $4 million, the risk is worth taking...This area(gene therapy)is the most depressed, e.g., CEGE, TGEN, GMED, etc...Yet,the large pharmas are clearly targeting this area...With Avigen your downside is a fat $2 1/2...On the other side, any corporate alliance or research supporting the efficacy of gene therapy would provide substantial reward... |
